JAK1 Inhibitor for Large Inflammatory Liver Adenomas

We are studying whether the oral medication baricitinib can help reduce the size of large inflammatory liver adenomas in patients. This trial also looks at the safety and effectiveness of this treatment compared to standard care.

>2 years 6-10 visits Efficacy phase (II)No Placebo Cost Reimbursement Standard Medicines OralGastroenterologyHepatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Olumiant

Olumiant is a medicine used to treat moderate to severe rheumatoid arthritis, helping reduce joint swelling and pain.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Baricitinib

Baricitinib is a substance that reduces immune-driven inflammation to treat rheumatoid arthritis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Assistance Publique Hopitaux De Paris

Médecine Nucléaire

Bagnolet, France

Centre Hospitalier Universitaire De Bordeaux

Hepatogastroenterologie

Canéjan, France

Centre Hospitalier Universitaire De Bordeaux

Radiologie

Canéjan, France

Sponsor: Assistance Publique Hopitaux De Paris

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.